Carl N. Kraus - Oct 15, 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
Chief Medical Officer
Signature
/s/ Lori Braender, as Attorney-In-Fact
Stock symbol
AQST
Transactions as of
Oct 15, 2025
Transactions value $
-$141,904
Form type
4
Date filed
10/17/2025, 02:01 PM
Previous filing
Aug 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kraus Carl N Chief Medical Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN /s/ Lori Braender, as Attorney-In-Fact 2025-10-16 0001946475

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Sale -$142K -20.3K -6.7% $7.00 282K Oct 15, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
F2 The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.